Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-world Data on Gi(l)Otrif® Dose Adjustment in First-line Treatment, TKI-naïve, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations

NCT02751879 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02751879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02751879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-world Data on Gi(l)Otrif® Dose Adjustment in First-line Treatment, TKI-naïve, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
November 24, 2016
Completion date
September 30, 2017
Enrollment
228 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung